Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis

Clinical Infectious Diseases

Volumn 52, Issue 6, 2011, Pages 717-725

  Koh, Gavin C K W ^a,b,c,e,g   Maude, Rapeephan R ^e   Schreiber, M Fernanda ^b   Limmathurotsakul, Direk ^e   Wiersinga, W Joost ^g   Wuthiekanun, Vanaporn ^e   Lee, Sue J ^d,e   Mahavanakul, Weera ^f   Chaowagul, Wipada ^e,f   Chierakul, Wirongrong ^e   White, Nicholas J ^d   Van Der Poll, Tom ^g   Day, Nicholas P J ^d,e   Dougan, Gordon ^b   Peacock, Sharon J ^a,b,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Sappasitthiprasong Hospital   (Thailand)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; METFORMIN; SULFONYLUREA;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BURKHOLDERIA INFECTION; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SURVIVAL; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; BURKHOLDERIA PSEUDOMALLEI; COHORT STUDIES; FEMALE; GLYBURIDE; HUMANS; MALE; MELIOIDOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79953764920     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq192     Document Type: Article

References (32)

1. Wiersinga WJ, van der Poll T. Is the septic response good or bad? Curr Infect Dis Rep 2007; 9:366-73. (Pubitemid 47422768)
2. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the cryopyrin/ NALP3 inflammasome. J Cell Biol 2009; 187:61-70.
3. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999; 29:408-13. (Pubitemid 29380208)
4. Victora CG, Huttly SR, Fuchs SC, Olint MTA. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol 1997; 26:224-7. (Pubitemid 27129589)
5. McCane DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994; 308:1323-8.
6. Limmathurotsakul D, Wuthiekanun V, Chierakul W, et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol 2005; 43:2274-6. (Pubitemid 40656240)
7. Warrillow S, Egi M, Bellomo R. Randomized, double-blind, placebocontrolled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 2006; 34:980-5.
8. Morelli A, Lange M, Ertmer C, et al. Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. Shock 2007; 28:530-5. (Pubitemid 350287437)
9. Esper A, Moss M, Martin G. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care 2009; 13:R18.
10. Moss M, Guidot DM, Steinberg KP, et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 2000; 28:2187-92. (Pubitemid 30604414)
11. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform trigering activation of inflammatory caspases and processing of proIL-b. Mol Cell 2002; 10:417-26. (Pubitemid 35007355)
12. Kikkawa T, Suzuki Y, Makabe H, et al. Assessment of IL-18 values in septic acute lung injury/acute respiratory distress syndrome patients. Crit Care 2009; 13:P368.
13. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of in- flammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107:1062-73.
14. Koh Y, Hybertson BM, Jepson EK, Cho OJ, Repine JE. Cytokineinduced neutrophil chemoattractant is necessary for interleukin-1- induced lung leak in rats. J Appl Physiol 1995; 79:472-8.
15. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-a-activated vascular endothelium under flow. J Leukoc Biol 2005; 106:584-92. (Pubitemid 40981255)
16. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR. Proin- flammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 1996; 153:1850-6. (Pubitemid 26187910)
17. Leff JA, Baer JW, Bodman ME, et al. Interleukin-1-induced lung neutrophil accumulation and oxygen metabolite-mediated lung leak in rats. Am J Physiol Lung Cell Mol Physiol 1994; 266: L2-8.
18. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007; 195:99-107. (Pubitemid 44958231)
19. Pompermayer K, Amaral FA, Fagundes CT, et al. Effects of the treatment with glibenclamide, an ATP-sensitive potassium channel blocker, on intestinal ischemia and reperfusion injury. Eur J Pharmacol 2007; 556:215-22. (Pubitemid 46074006)
20. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-49. (Pubitemid 30408719)
21. Riddle MC. Sulphonylureas differ in effects on ischemic preconditioning- is it time to retire glyburide? J Clin Endocrinol Metab 2003; 88:528-30. (Pubitemid 36207784)
22. Muruve DA, Pétrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452:103-7. (Pubitemid 351355095)
23. Haskó G, Deitch EA, Németh ZH, Kuhel DG, Szabó C. Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages. J Pharmacol Exp Ther 2002; 301:103-10. (Pubitemid 34250285)
24. Hamon Y, Luciani MF, Becq F, Verrier B, Rubartelli A, Chimini G. Interleukin-1b secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 1997; 90:2911-5. (Pubitemid 27444184)
25. Di Virgillo F. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci 2007; 28:465-72.
26. Jiang H, Zhu AG, Mamczur M, Falck JR, Lerea KM, McGiff JC. Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 2007; 151:1033-40. (Pubitemid 47195527)
27. Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24. (Pubitemid 27310249)
28. McNicholas CM, Guggino WB, Schweibert EM, Hebert SC, Giebisch G, Egan ME. Sensitivity of a renal K1 channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cystic fibrosis transmembrane regulator. Proc Natl Acad Sci USA 1996; 93:8083-8.
29. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 2001; 132:778-84. (Pubitemid 32165194)
30. Melin P, Hosy E, Vivaudou M, Becq F. CFTR inhibition by glibenclamide requires a positive charge in cytoplasmic loop three. Biochim Biophys Acta 2007; 1768:2438-6.
31. Dal-Secco D, Cunha TM, Freitas A, et al. Hydrogen sulfide augments neutrophil migration through enhancement of adhesion molecule expression and prevention of CXCR2 internalization: role of ATPsensitive potassium channels. J Immunol 2008; 181:4287-98.
32. Cole SR, Hernán MA. Fallibility in estimating direct effects. Int J Epidemiol 2002; 31:163-5. (Pubitemid 34284920)